… appointed Managing Director at Lundbeck, a global pharmaceutical company … position. Having worked with Lundbeck for twelve years, she … incredible organization that is Lundbeck Australia,” Dignum wrote on … people in +50 countries,” Lundbeck says on its website. …

… each. Longboard is now Lundbeck’s wholly owned subsidiary, … through a merger with Lundbeck’s subsidiary, Langkawi Corporation … facilities. The acquisition provides Lundbeck access to bexicaserin, a … around 480 participants. Lundbeck president and CEO Charl …

… Administration earlier this year and Lundbeck said the asset holds … from severe brain disorders.” Lundbeck said it expects to launch … ’s shares skyrocketed 51%. Lundbeck said it would offer $60 … the end of 2024. Lundbeck, which manufactures migraine treatment …

… a strategic milestone for Lundbeck, enhancing and complementing … the acquisition of Longboard, Lundbeck gains access to bexicaserin, … . This aligns with Lundbeck’s expertise in delivering … CEO of Longboard. “Lundbeck’s remarkable capabilities will accelerate …

… their support and partnership. Lundbeck’s remarkable capabilities will … a strategic milestone for Lundbeck, enhancing and complementing … the acquisition of Longboard, Lundbeck gains access to bexicaserin, … . This aligns with Lundbeck’s expertise in delivering …

… capabilities within neuro-rare conditions. Lundbeck has initiated a tender offer … for their support and partnership. “Lundbeck’s remarkable capabilities will accelerate … customary conditions. In March 2024, Lundbeck and Otsuka Pharmaceuticals Europe’s …

… Danish pharmaceutical company H. Lundbeck A/S has … diseases. bexicaserin complements the Lundbeck product line in the middle … as legal advisor to Lundbeck. Evercore and Centerview Partners … Longboard's advisors. Lundbeck is a Danish pharmaceutical …

… the epilepsy treatment landscape. Lundbeck projects that bexicaserin could … Bexicaserin’s development positions Lundbeck against several other pharmaceutical … Outlook: Strategic Vision for Lundbeck Lundbeck’s acquisition of Longboard Pharmaceuticals …

… were licensed from Arena Pharmaceuticals. Lundbeck focuses on neuroscience drugs. The … ’s annual report. Within neuroscience, Lundbeck executives have identified rare neurological … an opportunity for pipeline expansion. Lundbeck projects a fourth quarter 2028 …

… The acquisition, announced Monday, has Lundbeck paying $60 in cash for … , Lennox-Gastaut syndrome. But Lundbeck believes it has the ability … will become a cornerstone in Lundbeck’s neuro-rare franchise, … following year. Two of Lundbeck’s other main products, …